Capturing Pharmaceutical Emerging Markets with Data

Developing a drug and introducing it to the marketplace is extremely expensive and time-consuming. The average cost to develop a new drug is between four and 11 billion dollars, and it takes 12 years from discovery to market. Fewer than one in 10 drugs that start human clinical trials make it to market. Given the enormous cost to develop a new drug, mature pharma markets are stagnating.

Spotlight

Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement.

Other Infographics
news image

Smart Pharmacovigilance

Infographic | May 23, 2021

Pharmacovigilance (PV) is essential to all life science organizations, ensuring that patients' health comes first. Various trends in global healthcare have transformed today’s PV function into a corporate asset that enhances brand value and contributes to new growth opportunities. However, existing safety systems impose a significant cost burden to operate.

Read More
news image

Summary of Chloroquine and Hydroxychloroquine Drug-Drug Interactions

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.

Read More
news image

2021 global life sciences outlook

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Read More
news image

Pharmaceutical Industry World Economy Scenario

Infographic | May 20, 2022

This product titled One Page Pharmaceutical Industry World Economy Scenario Report Infographic PPT PDF Document is a completely editable document in A4 size designed in Powerpoint.

Read More
news image

Taking Pharmacy Benefits on a New Ride

Infographic | December 1, 2019

Rideshare companies like Uber and Lyft challenged the old way of doing things with a new approach. It’s not just about getting from point A to point B anymore, it’s about the experience, convenience and added value. The same applies to pass-through PBMs (pharmacy benefit managers) that are challenging the status quo to make prescriptions more affordable..

Read More
news image

Latest Improvement on Pharmanews to Serve You Better

Infographic | April 16, 2020

Poised to give our readers and advertisers better services in spite of the COVID19 pandemic, Pharmanews–your global health journal has continued to improve on its services in terms of healthcare information dissemination, by keeping readers abreast of latest development in public health, especially on how to stay safe from the novel Coronavirus, as well as expanding our reach to over 250,000 readers per month.

Read More

Spotlight

Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement.

Events